IN REMEMBRANCE
Dr. Mikhail (Misha) Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time. Full Tribute
TRIBUTES & MEMORIES
NOTABLE CONTRIBUTIONS
Dr. Blagosklonny has published more than 290 papers in peer-reviewed journals: PubMed.
Dr. Blagosklonny’s most essential publications on the concept of normal cells protection:
- 1999: Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal
- 2001: Exploiting cancer cell cycling for selective protection of normal cells
- 2002: Cyclotherapy: protection of normal cells and unshielding of cancer cells
- 2003: Tissue-selective therapy of cancer
- 2004: Gefitinib (Iressa) in oncogene-addictive cancers and therapy for common cancers
- 2005: Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance
- 2008: Targeting the absence and therapeutic engineering for cancer therapy
- 2011: Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
- 2023: Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Essential publications by Dr. Blagosklonny on hyperfunction theory of aging:
- 2006: Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition
- 2007: Paradoxes of aging
- 2009: TOR-driven aging: speeding car without brakes
- 2009: Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration
- 2009: Growth and aging: a common molecular mechanism
- 2010: Rapamycin and quasi-programmed aging: four years later
- 2010: Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal
- 2010: Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans)
- 2010: Rapamycin extends maximal lifespan in cancer-prone mice
- 2012: Answering the ultimate question "what is the proximal cause of aging?"
- 2012: Prospective treatment of age-related diseases by slowing down aging
- 2013: Rapamycin extends life- and health span because it slows aging
- 2013: MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer
- 2013: Aging is not programmed: genetic pseudo-program is a shadow of developmental growth
- 2014: Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet
- 2014: Geroconversion: irreversible step to cellular senescence
- 2018: Rapamycin, proliferation and geroconversion to senescence
- 2021: DNA- and telomere-damage does not limit lifespan: evidence from rapamycin
- 2021: The hyperfunction theory of aging: three common misconceptions
- 2022: Cell senescence, rapamycin and hyperfunction theory of aging
- 2022: Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice
- 2023: Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?
- 2023: Are menopause, aging and prostate cancer diseases?
EDITORIAL LEADERSHIP
- 2002: Editor-in-Chief of Cell Cycle, a position he held for more than 16 years.
- 2009: Founding Editor-in-Chief of Aging.
- 2010: Founding Editor-in-Chief of Oncotarget.
- 2012: Founding Editor-in-Chief of Oncoscience.
Dr. Blagosklonny has also served as an associate editor or a member of the editorial board of multiple journals, including Cancer Research, International Journal of Cancer, Leukemia, Cell Death Differentiation, Cancer Biology & Therapy, American Journal of Pathology, Autophagy, and others.